Compare · IBM vs OMCL
IBM vs OMCL
Side-by-side comparison of International Business Machines Corporation (IBM) and Omnicell Inc. (OMCL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IBM and OMCL operate in Computer Manufacturing (Technology), so they compete in similar markets.
- IBM is the larger of the two at $217.67B, about 137.7x OMCL ($1.58B).
- Over the past year, IBM is down 3.5% and OMCL is up 4.8% - OMCL leads by 8.3 points.
- IBM has been more active in the news (10 items in the past 4 weeks vs 5 for OMCL).
- IBM has more recent analyst coverage (25 ratings vs 24 for OMCL).
- Company
- International Business Machines Corporation
- Omnicell Inc.
- Price
- $231.03-1.93%
- $34.66-2.48%
- Market cap
- $217.67B
- $1.58B
- 1M return
- +7.92%
- -15.30%
- 1Y return
- -3.54%
- +4.76%
- Industry
- Computer Manufacturing
- Computer Manufacturing
- Exchange
- NYSE
- NASDAQ
- IPO
- 2001
- News (4w)
- 10
- 5
- Recent ratings
- 25
- 24
International Business Machines Corporation
International Business Machines Corporation provides integrated solutions and services worldwide. Its Cloud & Cognitive Software segment offers software for vertical and domain-specific solutions in various application areas; and customer information control system and storage, and analytics and integration software solutions to support client mission on-premise workloads in banking, airline, and retail industries. It also offers middleware and data platform software, including Red Hat that enables the operation of clients' hybrid multi-cloud environments; and Cloud Paks, WebSphere distributed, and analytics platform software, such as DB2 distributed, information integration, and enterprise content management, as well as IoT, Blockchain and AI/Watson platforms. The company's Global Business Services segment offers business consulting services; system integration, application management, maintenance, and support services for packaged software; and finance, procurement, talent and engagement, and industry-specific business process outsourcing services. Its Global Technology Services segment provides IT infrastructure and platform services; and project, managed, outsourcing, and cloud-delivered services for enterprise IT infrastructure environments; and IT infrastructure support services. The company's Systems segment offers servers for businesses, cloud service providers, and scientific computing organizations; data storage products and solutions; and z/OS, an enterprise operating system, as well as Linux. Its Global Financing segment provides lease, installment payment, loan financing, short-term working capital financing, and remanufacturing and remarketing services. The company has a collaboration alliance with GK Software SE to enhance retail innovation and customer omnichannel experience with hybrid cloud technology. The company was formerly known as Computing-Tabulating-Recording Co. The company was incorporated in 1911 and is headquartered in Armonk, New York.
Omnicell Inc.
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. In addition, the company provides automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; single dose automation solutions to fill and label for incoming prescriptions; semi-automated filling equipment for the long-term care institutional pharmacy; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Latest IBM
- IBM Unveils Next Generation Dual-Architecture Processor for IBM Z and LinuxONE
- IBM Study: Sports Fans Want Streamlined Digital Experiences as Platform Choices Expand
- IBM and the USTA Introduce New AI-Powered Fan Experiences for 2026 US Open
- IBM Connects Its First Modular Cryogenic Systems in Milestone Toward Fault-Tolerant Quantum Computing
- IBM Partners with OpenAI to Accelerate Secure AI Deployment for Enterprises Across Core Operations
- SEC Form 424B5 filed by International Business Machines Corporation
- IBM and Together AI Sign Multi-Year Agreement to Scale Open-Source AI Inference with NVIDIA AI Infrastructure on IBM Cloud
- SEC Form FWP filed by International Business Machines Corporation
- SEC Form 424B3 filed by International Business Machines Corporation
- IBM and Red Hat Offer Lightwell at No Charge to Universities, NGOs and Think Tanks
Latest OMCL
- EVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J covered exercise/tax liability with 4,025 shares, decreasing direct ownership by 4% to 108,985 units (SEC Form 4)
- VP, Chief Accounting Officer Nutt Brian H. covered exercise/tax liability with 937 shares, decreasing direct ownership by 4% to 22,266 units (SEC Form 4)
- President & COO Njoku Nnamdi covered exercise/tax liability with 3,670 shares and sold $113,609 worth of shares (3,083 units at $36.85) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 161,224 units (SEC Form 4)
- CHAIRMAN, CEO Lipps Randall A covered exercise/tax liability with 12,350 shares, decreasing direct ownership by 2% to 511,096 units (SEC Form 4)
- SEC Form 10-Q filed by Omnicell Inc.
- EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination
- Omnicell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Omnicell Announces Second Quarter 2026 Financial Results
- CHAIRMAN, CEO Lipps Randall A sold $470,000 worth of shares (10,000 units at $47.00) as part of a pre-agreed trading plan (SEC Form 4)
- Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026